Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Jbi-778

Phase 1

JJubilant Therapeutics Inc.

2

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Brain Metastases From Solid TumorsNot yet recruiting

EGFR Activating MutationRecruiting

Brain Metastases From Solid TumorsPreclinical

Not yet recruiting

EGFR Activating MutationPhase 1

Recruiting

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

EGFR Activating Mutation

NCT07755397

Q1 2030

PreclinicalNot yet recruiting

Brain Metastases From Solid Tumors

NCT07751744

Clinical

Trials by Indication[1]

EGFR Activating Mutation1 trial

A Phase 1, Multicenter, Open-Label, Dose-Escalation/Consolidation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Orally Administered JBI-778 in EGFR Mutated Lung Cancer Patients With or Without Brain Metastasis, Isocitrate Dehydrogenase (IDH) Mutated WHO Grade 3/4 Recurrent Glioma and Adenoid Cystic Carcinoma (ACC)

Recruiting·JJubilant Therapeutics India Limited·Phase 1·NCT07755397·30 enrolled

Brain Metastases From Solid Tumors1 trial

A Phase 1/2, Multicenter, Open-Label, Dose-Escalation/Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered JBI-778 in Patients With Brain Metastasis, Leptomeningeal Disease, or High Grade Recurrent Glioma

Not yet recruiting·JJubilant Therapeutics Inc.·Preclinical·NCT07751744·113 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Jbi-778. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Jbi-778. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Jubilant Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: JJubilant Therapeutics Inc.

Related News